Fig. 1

EZH2 gain was an adverse prognostic factor of BRAF V600E mutated melanoma. a Correlation of EZH2 gain with clinicopathological features in patients with BRAF V600E-mutated melanoma was shown by heat map. b Comparison of the OS and DFS of patients with different EZH2 gain levels was conducted by the Kaplan–Meier method. [i, ii] No EZH2 copy number gain and gain groups. [iii, iv] No EZH2 copy number gain, gain and high gain groups